Australian researchers have made a groundbreaking discovery in the field of breast cancer research, identifying a molecular switch that drives the spread of triple-negative breast cancer, a subtype responsible for some of the poorest outcomes. This breakthrough could lead to the development of new treatments for this aggressive form of cancer.
Key Insights
The study found that patients with low levels of miR-342, a naturally occurring molecule, and high activity of the E2F pathway, a cancer-driving pathway, were more likely to develop metastatic disease. However, restoring miR-342 levels was shown to reduce the spread of breast cancer to other organs in preclinical models, offering a promising avenue for future research and treatment development.
